CYTK - サイトキネティクス （Cytokinetics Incorporated） サイトキネティクスCYTKのチャート
CYTKの企業情報
| symbol | CYTK |
|---|---|
| 会社名 | Cytokinetics Inc （サイトキネティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 サイトカイネティックス(Cytokinetics Incorporated)は後期バイオ医薬品会社である。同社は筋肉のパフォーマンスが損害あるいは低下などの衰弱性疾患の潜在的治療法としてのファースト・イン・クラス筋肉活性化因子の発見、開発、商業化などを行う。重病治療のために筋肉機能を調節する小分子治療法の発見と開発を中心とする。同社の臨床階段の薬品候補はtirasemtiv、CK-2127107とomecamtiv mecarbilを含む。同社は筋萎縮性側索硬化症（ALS）の治療のためのティラセミチブ薬候補を開発する。脊髄性筋萎縮、慢性閉塞性肺疾患およびALSの潜在的治療薬としてCK-2127107を開発する。Omecamtiv mecarbilは心不全の治療するための心筋ミオシンアクチベーターである。 サイトキネティクスは、米国の医薬品会社。心不全治療を適応とする医薬品薬候補の発見、開発、商業化に従事。主に、筋萎縮性側索硬化症に対する｢Tirasemtiv(正式名称：CK-2017357)｣の臨床試験に焦点を当てている。本社はカリフォルニア州サウスサンフランシスコ。 Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. |
| 本社所在地 | 280 East Grand Avenue South San Francisco CA 94080 USA |
| 代表者氏名 | Leonard Patrick Gage レナード・パトリック・ゲージ |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 650-624-3000 |
| 設立年月日 | 35643 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2004年 |
| 従業員数 | 137人 |
| url | www.cytokinetics.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cytk |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -112.14400 |
| 終値（lastsale） | 8.23 |
| 時価総額（marketcap） | 449588415.31 |
| 時価総額 | 時価総額（百万ドル） 429.92230 |
| 売上高 | 売上高（百万ドル） 17.64500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 230.34630 |
| 当期純利益 | 当期純利益（百万ドル） -130.64600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cytokinetics Inc. revenues increased 59% to $11.5M. Net loss increased 5% to $57.8M. Revenues reflect Revenue Sales of Goods_Serv increase from $818K to $8.3M. Higher net loss reflects Research and development increase of 12% to $43.7M (expense) Non-cash interest expense on liability r increase of 41% to $8.5M (expense) General and administrative increase of 5% to $17.3M (expense). |
CYTKのテクニカル分析
CYTKのニュース
Cytokinetics''s Omecamtiv Mecarbil Shows No Effect On Exercise Capacity In Heart Failure Patients 2022/04/04 12:57:50 Benzinga
Cytokinetics Incorporated (NASDAQ: CYTK ) announced the full results from the METEORIC-HF Phase 3 trial of omecamtiv mecarbil in patients with heart failure with reduced ejection fraction (HFrEF). METEORIC-HF evaluated the effect of treatment with omecamtiv mecarbil compared to placebo on exercise capacity. After 20 weeks of treatment, no effect of omecamtiv mecarbil on exercise capacity was observed versus placebo. Also See: Cytokinetics Posts Cohort 3 Data From Aficamten Trial … Full story available on Benzinga.com
Cytokinetics Incorporated (NASDAQ: CYTK) Shares Are Set To Rise By 2022 2022/03/12 14:00:00 Stocks Register
Cytokinetics Incorporated (NASDAQ:CYTK) shares, rose in value on Friday, 03/11/22, with the stock price down by -0.98% to the previous day’s close as strong demand from buyers drove the stock to $37.50. Actively observing the price movement in the last trading, the stock closed the session at $37.87, falling within a range of $37.08 and … Cytokinetics Incorporated (NASDAQ: CYTK) Shares Are Set To Rise By 2022 Read More »
Cytokinetics to Participate in Upcoming Investor Conferences 2022/03/08 21:00:00 GlobeNewswire
SOUTH SAN FRANCISCO, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the virtual Oppenheimer 32 nd Annual Healthcare Conference on Tuesday, March 15, 2022 at 11:20 am ET and participate in a fireside chat at the Barclays Global Healthcare Conference on Wednesday, March 16, 2022 at 11:45 am ET at the Loews Miami Beach Hotel in Miami Beach.
Cytokinetics, Incorporated (CYTK) CEO Robert Blum on Q4 2021 Results - Earnings Call Transcript 2022/02/25 14:35:22 Seeking Alpha
Cytokinetics Inc Shares Climb 0.9% Past Previous 52-Week High - Market Mover 2021/12/28 01:27:10 Kwhen Finance
Cytokinetics Inc (CYTK) shares closed 0.9% higher than its previous 52 week high, giving the company a market cap of $3B. The stock is currently up 114.9% year-to-date, up 113.3% over the past 12 months, and up 260.2% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 32.6% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -566.7% The company's stock price performance over the past 12 months beats the peer average by -514.7%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
HC Wainwright Raises Cytokinetics (NASDAQ:CYTK) Price Target to $69.00 2021/12/24 07:52:43 ETF Daily News
Cytokinetics (NASDAQ:CYTK) had its target price hoisted by HC Wainwright from $62.00 to $69.00 in a report published on Tuesday morning, Analyst Price Targets reports. The brokerage currently has a buy rating on the biopharmaceutical companys stock. Several other research firms have also recently weighed in on CYTK. Jefferies Financial Group started coverage on Cytokinetics [] The post HC Wainwright Raises Cytokinetics (NASDAQ:CYTK) Price Target to $69.00 appeared first on ETF Daily News .
Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sells $675,000.00 in Stock 2021/12/24 01:08:42 Dakota Financial News
Cytokinetics, Incorporated (NASDAQ:CYTK) Director Edward M. Md Kaye sold 15,000 shares of the stock in a transaction on Thursday, December 23rd. The stock was sold at an average price of $45.00, for a total value of $675,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. []
Oppenheimer Initiates Coverage on Cytokinetics (NASDAQ:CYTK) 2021/12/23 07:56:42 ETF Daily News
Equities researchers at Oppenheimer started coverage on shares of Cytokinetics (NASDAQ:CYTK) in a report released on Tuesday, The Fly reports. The brokerage set an outperform rating and a $55.00 price target on the biopharmaceutical companys stock. Oppenheimers price target indicates a potential upside of 24.94% from the companys current price. CYTK has been the subject [] The post Oppenheimer Initiates Coverage on Cytokinetics (NASDAQ:CYTK) appeared first on ETF Daily News .
Cytokinetics (NASDAQ:CYTK) Hits New 1-Year High on Analyst Upgrade 2021/12/22 18:10:42 Transcript Daily
Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) reached a new 52-week high on Wednesday after HC Wainwright raised their price target on the stock from $62.00 to $69.00. HC Wainwright currently has a buy rating on the stock. Cytokinetics traded as high as $43.70 and last traded at $43.70, with a volume of 10808 shares traded. The []
Cytokinetics Inc Shares Climb 0.9% Past Previous 52-Week High - Market Mover 2021/12/28 01:27:10 Kwhen Finance
Cytokinetics Inc (CYTK) shares closed 0.9% higher than its previous 52 week high, giving the company a market cap of $3B. The stock is currently up 114.9% year-to-date, up 113.3% over the past 12 months, and up 260.2% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 32.6% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -566.7% The company's stock price performance over the past 12 months beats the peer average by -514.7%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
HC Wainwright Raises Cytokinetics (NASDAQ:CYTK) Price Target to $69.00 2021/12/24 07:52:43 ETF Daily News
Cytokinetics (NASDAQ:CYTK) had its target price hoisted by HC Wainwright from $62.00 to $69.00 in a report published on Tuesday morning, Analyst Price Targets reports. The brokerage currently has a buy rating on the biopharmaceutical companys stock. Several other research firms have also recently weighed in on CYTK. Jefferies Financial Group started coverage on Cytokinetics [] The post HC Wainwright Raises Cytokinetics (NASDAQ:CYTK) Price Target to $69.00 appeared first on ETF Daily News .
Cytokinetics, Incorporated (NASDAQ:CYTK) Director Sells $675,000.00 in Stock 2021/12/24 01:08:42 Dakota Financial News
Cytokinetics, Incorporated (NASDAQ:CYTK) Director Edward M. Md Kaye sold 15,000 shares of the stock in a transaction on Thursday, December 23rd. The stock was sold at an average price of $45.00, for a total value of $675,000.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. []
Oppenheimer Initiates Coverage on Cytokinetics (NASDAQ:CYTK) 2021/12/23 07:56:42 ETF Daily News
Equities researchers at Oppenheimer started coverage on shares of Cytokinetics (NASDAQ:CYTK) in a report released on Tuesday, The Fly reports. The brokerage set an outperform rating and a $55.00 price target on the biopharmaceutical companys stock. Oppenheimers price target indicates a potential upside of 24.94% from the companys current price. CYTK has been the subject [] The post Oppenheimer Initiates Coverage on Cytokinetics (NASDAQ:CYTK) appeared first on ETF Daily News .
Cytokinetics (NASDAQ:CYTK) Hits New 1-Year High on Analyst Upgrade 2021/12/22 18:10:42 Transcript Daily
Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) reached a new 52-week high on Wednesday after HC Wainwright raised their price target on the stock from $62.00 to $69.00. HC Wainwright currently has a buy rating on the stock. Cytokinetics traded as high as $43.70 and last traded at $43.70, with a volume of 10808 shares traded. The []